10/528644

Docket No.: 428.1049

### JC05 Rec'd PCT/PTO 18 MAR 2005 UNITED STATES PATENT & TRADEMARK OFFICE

Examiner: Unknown

Art Unit: Unknown

Applicant:

SUNG, Young Chul, et al.

Serial No.:

To be assigned

Filed

Herewith

For:

A VACCINE ENHANCING THE PROTECTIVE IMMUNITY TO HEPATITIS C VIRUS USING PLASMID DNA AND RECOMBINANT

**ADENOVIRUS** 

### INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 March 18, 2005

Sir:

Pursuant to M.P.E.P. §609 and 37 C.F.R. §§1.56, 1.97-1.99, Applicants herewith submit forms PTO-1449 (2 pages), which lists references cited in the International Search Report (ISR) dated December 10, 2003, International Preliminary Examination Report (IPER) dated April 7, 2004 and of which Applicants are aware of for the application. A copy of the ISR and IPER are enclosed herewith. It is noted that the Applicants have not enclosed a copy of the U.S. patents cited on form PTO-1449.

This submission does not represent that a search has been made or that no better art exists. While the term "references" is used in citing the documents called to the Examiner's attention herein, Applicants do not make any admission that each or all of them are "prior art" references within the meaning of the statutory and case law.

Applicants reserves the right to contend, where appropriate, that a patent asserted against any claim of the present application is not prior art under the facts and the law.

## 10/528644 JC05 Rec'd PCT/PTO 18 MAR 2005

Applicants also reserve the right to present appropriate arguments and/or evidence to establish patentability over the references, should one or more of the references be applied against the claims of the present application.

Applicants request that the Examiner independently determine those items which the Examiner would consider the most pertinent of all the references cited herein.

This Information Disclosure Statement is filed with the application and is therefore within three (3) months of the filing date of this application. Accordingly, this document complies with the requirements of 37 C.F.R. Section 1.97(b). It is respectfully requested that the references cited in the accompanying PTO-1449 form be considered and made of record.

Respectfully submitted,

MUSERLIAN, LUCAS & MERCANTI, LLP

Michael N. Mercanti Registration No. 33,966

MUSERLIAN, LUCAS & MERCANTI, LLP

475 Park Avenue South New York, NY 10016 Phone: 212-661-8000

Fax: 212-661-8002

"Express Mail" mailing label no. EV 576 695 448 US Date of Deposit March 18, 2005

I hereby certify that this correspondence and/or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, in an envelope addressed to: "Commissioner for Patents, P.O. Box 1450

Alexandria, VA 22313-1450".

MUSERLIAN, LUCAS & MER

By: Carl Santos

# INFORMATION DISCLOSU CITATION (Use several sheets if necessary)

Docket Number (Option 05 Rec'd POT/PTO unibes MAR 2005
428.1049
To be assigned 2005

Applicant(s)
SUNG, Young Chul, et al.

10/528644#3

Filing Date

Herewith

Unknown

_						1101011					
				U.S.	. PATENT DO	CUMENTS					
*EXAMINER INITIAL	REF	DOCUMENT NU	JMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO		
					<u> </u>						
			-								
								1			
				U.S. PATENT	APPLICATI	ON PUBLICATION	is				
*EXAMINER INITIAL	REF	DOCUMENT NU	JMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO		
										`	
	L			FOREI	GN PATENT	DOCUMENTS		<del>.l</del>			
	REF	DOCUMENT NU	JMBER	DATE		COUNTRY	CLASS	SUBCLASS	Translation YES NO		
					E						
N											
	<u> </u>			OTHER D	OCUMENTS	(Including A	luthor, Title, Date, Peri	tinent Pages, Etc		L	
		Xavier Forn VIRUS (HC	s, et al., VAC V) ENVELC	CINATION OF OPE E2 PROTEI	CHIMPAN N MODIFII	ZEES WITH PLA	ASMID DNA ENCO Vo. 32, No. 3, 2000	DING THE H	EPATITIS	3 C	
		A1				,					
Christine B. Bruce, et al., REPLICATION-DEFICIENT RECOMBINANT ADENOVIRUSES EXPRESSING TH HUMAN IMMUNODEFICIENCY VIRUS ENV ANTIGEN Journal of General Virology (1999), 80, 2621-2628,							ING THE 21-2628, P	rinted in			
	, Alb	Great Britai	n		<b>5 2</b> -		-	,, ,			
EXAMINER				D	DATE CONSIDERED						
TO A BAIRIE						*** MADED Continue		t situation if not i	- 200formou		
EXAMINE	.R: Initi	al if citation consider	ed, whether or	a not citation is in c	onformance v	vith MPEP Section 6'	العال: Draw line through	a citation if not i	a coniormar	ace and	

not considered. Include copy of this form with next communication to applicant.

#### CITATION INFORMATION DISCLOSU (Use several sheets if necessary)

not considered. Include copy of this form with next communication to applicant.

Docket Number (Optional) Applicant(s)
SUNG, Young Chul, et al.

Filing Date

Herewith

*EXAMINER		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	e, Date, Pertinent Pages, Etc.)					
INITIAL	А3	Nourredine Himoudi et al., CORNPARATIVE VACCINE STUDIES IN HLA-AZ CLUSTERED ORGANIZATION OF EPTIOPES Journal of Virology, Dec. 20	NPARATIVE VACCINE STUDIES IN HLA-A2.1-TRANSGENIC MICE REVEAL A OF EPTIOPES Journal of Virology, Dec. 2002, pp. 12735-12746; Vol. 76, No. 24					
	A4	John W. Shiver, et al., REPLICATION-INCOMPETENT ADENOVIRAL VACOANTI-IMMUNODEFICIENCY-VIRUS IMMUNITY, Nature, Vol. 415, 17 Janua	CINE VECTOR ELICITS EFFECTIVE ary 2002					
	A5	Rama Rao Amara, et al., CONTROL OF A MUCOSAL CHALLENGE AND PR MULTIPROTEIN DNA/MVA VACCINE, Science Vol. 292, 6 April 2001	REVENTION OF AIDS BY A					
	A6	Young Rim Seong, et al., IMMUNOGENICITY OF THE E1E2 PROTEINS OF I RECOMBINANT ADENOVIRUSES, Vaccine 19, (2001) 2955-2964	HEPATITIS C VIRUS EXPRESSED BY					
			·					
EXAMINER	1	DATE CONSIDERED	DATE CONSIDERED .					

P09B/REV04

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and